ePrints

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

Lookup NU author(s): Professor Stephen O'Brien

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O'Brien SG, Coffey T, Foroni L, Copland M

Publication type: Article

Publication status: Published

Journal: The Lancet Haematology

Year: 2017

Volume: 4

Issue: 7

Pages: e310-e316

Print publication date: 01/07/2017

Online publication date: 26/05/2017

Acceptance date: 02/04/2016

ISSN (electronic): 2352-3026

Publisher: Elsevier

URL: https://doi.org/10.1016/S2352-3026(17)30066-2

DOI: 10.1016/S2352-3026(17)30066-2

Altmetrics

Share